Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 6/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30933124 | 0.94 | APLNR (0.48) | NTSR1APLNROPRD1 | |
| SCHEMBL30933096 | 0.94 | APLNR (0.51) | NTSR1APLNROPRD1NTSR2 | |
| SCHEMBL30933105 | 0.94 | APLNR (0.48) | NTSR1APLNROPRD1NTSR2SORT1 | |
| SCHEMBL30933122 | 0.94 | APLNR (0.48) | APLNROPRD1 | |
| SCHEMBL30933143 | 0.93 | APLNR (0.53) | NTSR1APLNROPRD1 | |
| SCHEMBL30170451 | 0.93 | APLNR (0.53) | NTSR1APLNROPRD1 | |
| SCHEMBL30933156 | 0.93 | APLNR (0.53) | NTSR1APLNROPRD1 | |
| SCHEMBL30933095 | 0.91 | APLNR (0.54) | NTSR1APLNROPRD1 | |
| SCHEMBL22018499 | 0.91 | NTSR1 (0.45) | NTSR1APLNROPRD1 | |
| SCHEMBL30933116 | 0.91 | APLNR (0.51) | APLNROPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | claimed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | NTSR1 1091/4885APLNR 334/4885OPRD1 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.